Judith Greciet became the CEO of Onxeo SA (EPA:ONXEO) in 2011. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider growth that the business demonstrates. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels.
How Does Judith Greciet's Compensation Compare With Similar Sized Companies?
Our data indicates that Onxeo SA is worth €33m, and total annual CEO compensation was reported as €551k for the year to December 2018. We think total compensation is more important but we note that the CEO salary is lower, at €317k. We took a group of companies with market capitalizations below €182m, and calculated the median CEO total compensation to be €157k.
It would therefore appear that Onxeo SA pays Judith Greciet more than the median CEO remuneration at companies of a similar size, in the same market. However, this fact alone doesn't mean the remuneration is too high. We can better assess whether the pay is overly generous by looking into the underlying business performance.
You can see a visual representation of the CEO compensation at Onxeo, below.
Is Onxeo SA Growing?
On average over the last three years, Onxeo SA has grown earnings per share (EPS) by 9.1% each year (using a line of best fit). In the last year, its revenue is down 30%.
I would prefer it if there was revenue growth, but it is good to see EPS growth. In conclusion we can't form a strong opinion about business performance yet; but it's one worth watching. Shareholders might be interested in this free visualization of analyst forecasts.
Has Onxeo SA Been A Good Investment?
Given the total loss of 77% over three years, many shareholders in Onxeo SA are probably rather dissatisfied, to say the least. This suggests it would be unwise for the company to pay the CEO too generously.
We examined the amount Onxeo SA pays its CEO, and compared it to the amount paid by similar sized companies. As discussed above, we discovered that the company pays more than the median of that group.
While we have not been overly impressed by the business performance, the shareholder returns, over three years, have been disappointing. Shareholders may wish to consider further research. Although we don't think the CEO pay is too high, it is probably more on the generous side of things. If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Onxeo.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.